FIBRotic Interstitial Lung Disease and Nocturnal OXygen

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

102 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-17

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Home sleep studies - which allow the measurement of breathing while the person sleeps - will be performed on patients with fibrotic interstitial lung disease attending two of the UK's largest respiratory medicine services.The study will investigate at how symptoms, and breathing and exercise tests differ between these two groups after 12 months of study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

NCT05957198

Lung Diseases, Interstitial

COMPLETED

The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease

NCT07060079

Bronchial Asthma Bronchiectasis ILD +4 more

RECRUITING

Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study

NCT01110694

Idiopathic Pulmonary Fibrosis Idiopathic Non-specific Interstitial Pneumonitis

COMPLETED

Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT02058602

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1

ILD: Health Outcomes in Remote Digital Monitoring Versus Usual Care

NCT05662124

Interstitial Lung Disease

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The interstitial lung diseases are a group of diseases in which patients develop uncontrolled scarring (called fibrosis) within the lung. This causes failure of the lung and patients become progressively more breathless over time. The commonest of these diseases is idiopathic pulmonary fibrosis and this is a devastating condition with a survival of 3-5 years.

Many people with fibrotic interstitial lung diseases have disrupted sleep as well as low oxygen levels at night or obstructive sleep apnoea (OSA - pauses in breathing at night time due to obstruction of the upper airway).

Patients with low oxygen levels at night have a worse quality of life, with fatigue during the day and survive for less long.

102 patients from specialist clinics at Guy's and St Thomas' and the Royal Brompton and Harefield NHS Foundation Trusts will be recruited. This research is funded by a grant from the British Lung Foundation. The investigators aim to compare patients with and without low oxygen levels at night by observing how their disease and quality of life changes over a year.

Patients will be asked to complete a two-night home sleep study which will involve wearing a probe over the finger connected to a sensor on the wrist. Patients will also be provided with a home spirometer to measure their breathing at home daily during the study.

Lung function testing (which is part of normal clinical practice), a six-minute walk test and quality of life questionnaires will be performed at the beginning of the study. These investigations will be repeated at six and twelve months and this will tell us how night time oxygen levels affect the progression of the disease, quality of life, exercise tolerance, hospitalisation frequency and survival of these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis Obstructive Sleep Apnea Sleep Disturbance Sleep Hypoventilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MDT diagnosis of fibrotic interstitial lung disease including but not limited to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), chronic hypersensitivity pneumonitis (CHP), fibrotic organising pneumonia and unclassifiable fibrotic lung disease.
* Competent to provide written consent in English

Exclusion Criteria

* Presence of an underlying connective tissue disease
* Daytime/resting hypoxaemia with pO2 \<8.0
* Other indication for oxygen therapy
* 3% ODI \>15 events/hour studied or established on CPAP
* Predominant emphysema on CT
* Inability to provide informed consent or complete health-related quality of life questionnaires in English
* Current participation in a research project which might alter lung function or sleep study results

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No